Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax (2016 - 2025)
Historic Long-Term Deferred Tax for Ani Pharmaceuticals (ANIP) over the last 12 years, with Q3 2025 value amounting to $71.4 million.
- Ani Pharmaceuticals' Long-Term Deferred Tax rose 552.02% to $71.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year increase of 552.02%. This contributed to the annual value of $85.1 million for FY2024, which is 617.9% down from last year.
- Latest data reveals that Ani Pharmaceuticals reported Long-Term Deferred Tax of $71.4 million as of Q3 2025, which was up 552.02% from $92.0 million recorded in Q2 2025.
- Ani Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $92.0 million for Q2 2025, and its period low was $52.0 million during Q1 2021.
- Its 5-year average for Long-Term Deferred Tax is $77.2 million, with a median of $81.0 million in 2023.
- Per our database at Business Quant, Ani Pharmaceuticals' Long-Term Deferred Tax soared by 4140.48% in 2022 and then plummeted by 1982.25% in 2024.
- Ani Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $67.9 million in 2021, then rose by 19.76% to $81.4 million in 2022, then grew by 11.49% to $90.7 million in 2023, then dropped by 6.18% to $85.1 million in 2024, then dropped by 16.11% to $71.4 million in 2025.
- Its Long-Term Deferred Tax was $71.4 million in Q3 2025, compared to $92.0 million in Q2 2025 and $88.5 million in Q1 2025.